PANORAMIC Trial Collaborative Group, Butler, C C, Hobbs, F D R, Gbinigie, O A, Rahman, N M, Hayward, G, Richards, D B, Dorward, J, Lowe, D M, Standing, J F, Breuer, J, Khoo, S, Petrou, S, Hood, K, Nguyen-Van-Tam, J S, Patel, M G, Saville, B R, Marion, J, Ogburn, E, Allen, J, Rutter, H, Francis, N, Thomas, N P B, Evans, P, Dobson, M, Madden, T-A, Holmes, J, Harris, V, Png, M E, Lown, M, van Hecke, O, Detry, M A, Saunders, C T, Fitzgerald, M, Berry, N S, Mwandigha, L, Galal, U, Mort, S, Jani, B D, Hart, N D, Ahmed, H, Butler, D, McKenna, M, Chalk, J, Lavallee, L, Hadley, E, Cureton, L, Benysek, M, Andersson, M, Coates, M & Barrett, S 2023, ' Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial ', The Lancet, vol. 401, no. 10373, pp. 281-293 . https://doi.org/10.1016/S0140-6736(22)02597-1
Jones, R, Casbard, A, Carucci, M, Cox, C, Butler, R, Alchami, F, Madden, T-A, Bale, C, Bezecny, P, Joffe, J, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, Foxley, A & Howell, S 2020, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION) : a multicentre, randomised, controlled, phase 2 trial ', The Lancet Oncology, vol. 21, no. 3, pp. 345-357 . https://doi.org/10.1016/S1470-2045(19)30817-4